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Previously, we have established one e library by introducing
8 randomized sequences in upper stem and selected out a
series of RNA aptamers with higher afﬁnity to P protein
based on the in vitro SELEX in duck hepatitis B virus
(DHBV) system. Interestingly, we observed that only part of
these stronger binders support priming. In order to explore
structural determinants within e, all selected aptamers
were subjected to RNA structural mapping. We found that
an undamaged bulge is essential for initiating priming.
On the other hand, our study demonstrates that the
stronger binders with damaged bulge structure are able
to be potentially used as decoys for antiviral therapy by
interfering with the protein-priming process of wild type
DHBV. The given data also enable us to understand P-e
interactions during HBV replication in details.
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One of the important factors in safety of blood transfusion
is to use an additional sensitive screening test to identify
blood-born infective agents (like HBV). Although HBsAg
screening reduces the risk of HBV transmission, but HBsAg
negative blood donors may yet transmit HBV infection. The
aim of this study was to assess the possibility of using anti-
HBc as a screening test to improve the detection rate of
HBV infection in donated blood in city of Rasht, North of
Iran.
A total of 2,041 blood samples with negative result for
HBsAg, Anti-HCV, Anti-HIV I, II and RPR were collected
and used to detect anti-HBc Ab. If the result of anti-
HBc was positive, the samples were evaluated for HBVDNA
detection. DNA extraction was done by using a commercial
DNA extraction kit (Qiagen) and analyzed using a commercial
quantitative real-time PCR kit (artus HBV LC PCR Kit). The
positive sample was rechecked with a reliable and sensitive
homemade PCR kit.
The prevalence of anti-HBc Ab positive was 78/2041
(0.038%) by total anti-HBc Ab kit. One out of 78 anti-HBc Ab
positive sample was positive for HBVDNA when was checked
by real-time PCR and re-checked by homemade kit.
This study showed that the anti-HBc Ab positivity is lower
than many parts of Iran in Rasht. As anti-HBc Ab positive
blood donors may be a potential source of HBV transmission
further study for evaluation of HBVDNA in anti-HBc positive
blood units is strongly recommended.
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Background and Aims: The experimentation of antivirals,
new vaccine formulations and adjuvanted antigens, able to
elicit a speciﬁcally targeted cellular response or to interfere
with viral replication to break tolerance, is crucial for
immunotherapeutic approaches of Hepatitis B Virus (HBV)
infection. In this study we have applied the well recognized
preclinical model of the HBV, the Woodchuck (Marmota
monax) chronically infected from Woodchuck Hepatitis Virus
(WHV) with the aim to investigate the neutralization and
antiviral effects of Immune Genic Complex (IGC) composed
by preS/S antibodies and WHV particles in healthy and in
WHV chronically infected animals.
Methods: The characterized and quantiﬁed neutralization
mixture or IGC, was intravenously and intradermically
administered to four WHV negative and ﬁve WHV chronic
carriers. One animal was used as infection control.
Electro-chemi-luminescence immuno-assay (Elecsys, Roche
Molecular Diagnostics) to detect antibody to WHV core
antigen (WHcAb) and WHV “e” antigen (WHeAb), and
WHV “e” antigen (WHeAg) was used. WHV Real-Time PCR
was applied to determine the viral load every two weeks
after IGC administrations and PBMc proliferation assays was
performed making use of Core and PreS/S HBV regions
epitopes.
Results: The IGC administration obtained with the lowest
preS/S antibody amount (2.5mIU) showed, in WHV negative
woodchucks, better neutralization effects in terms of
WHeAg and viral load concentrations in all treated animals
in respect to the controls. The IGC administration in WHV
chronic carriers induced strong antiviral effect in three
out of ﬁve animals. The viral phylogenetic analysis (MEGA 4
program) of PreS/S region showed, in one animal, signiﬁcant
variation during follow up.
Conclusions: This newly designed experimental protocol
will be at the basis for further developments in the ﬁeld
of improvement of antigenic adjuvancy and of therapeutic
vaccines formulations.
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Background and Aims: In treatment of naive chronic
hepatitis B (CHB) patients, Entecavir shows good long term
viral suppression and low rate of development of resistance.
Its role in patients of CHB, who are exposed to lamivudine
therapy, is not clear. We studied the efﬁcacy of Entecavir
in this group of patients.
Methods: Ten patients who showed breakthrough
during lamivudine therapy, were treated with Entecavir
(1mg/day). The dose was modiﬁed in patients of renal
failure as required. HBVDNA quantitative levels were
done 3 monthly to assess adequacy and duration of viral
suppression. Assessment for Entecavir resistance deﬁned as
decline of <1 log10 copies/ml in 12 weeks or increase in
HBVDNA by 1 or 2 log levels were the primary end points.
Results: Of 10 patients (8 male; 8 HBeAg positive,
5 with compensated Liver Cirrhosis) who received Entecavir,
phenotypic resistance to Entecavir was seen in 5 (50%) over
a mean period of 12± 4.58 months. Of these 5, 4 were
